Columnist Highlights Analysis That Says Spinal Muscular Atrophy Treatments May Need To Be Priced Lower To Be Considered Cost-Effective.

February 26, 2019

Ed Silverman wrote in his Pharmalot column for STAT Plus (2/22, Subscription Publication) that “two medicines designed to treat spinal muscular atrophy, a rare and often fatal genetic disease affecting muscle strength and movement, would have to carry muc...